Combination targeted therapy for RAS-mutated colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of two targeted drugs (Tunlametinib and Fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and has not responded to two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced colorectal cancer with a RAS mutation
- You have tried two prior treatments that didn't work or you couldn't handle
- You have at least one measurable tumor on scans
- Your overall health is good enough to do daily activities (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Tunlametinib and an anti-EGFR antibody) in people with advanced pancreatic or colorectal cancer that has a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a combination treatment with tunlametinib for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a KRAS mutation and has not responded to standard therapy. The goal is to see if this targeted therapy can help shrink or slow the cancer.
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
Hear when a new CRC, Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.